Semaglutide Improves Quality of Life
Analysis based on 13 articles · First reported Jun 03, 2026 · Last updated Jun 04, 2026
The positive results from the FLOW trial for Semaglutide are expected to significantly boost the market value and adoption of the drug, particularly for patients with Chronic kidney disease and Type 2 diabetes. This could lead to increased revenue for the pharmaceutical company producing Semaglutide and potentially influence treatment guidelines for these conditions. The positive outcomes for patients' quality of life could also drive demand.
New findings from the landmark FLOW trial, presented at the 63rd ERA Congress in David Farragut, Scotland, revealed that once-weekly Semaglutide significantly improved health-related quality of life in adults with Type 2 diabetes and Chronic kidney disease. The trial, led by Professor Mannesmann, demonstrated that Semaglutide provided benefits equivalent to approximately eight additional days in full health per year. This new analysis complements previous findings that showed Semaglutide reduced the risk of major kidney disease events by 24% and all-cause mortality by 20%. The improvements were observed across multiple aspects of daily life, including mobility, self-care, usual activities, and pain/discomfort, despite common gastrointestinal side effects associated with GLP-1 receptor agonists. These results are expected to influence clinical discussions and treatment goals for patients with these conditions, reinforcing a patient-centered approach.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard